Neurology · AnticonvulsantRegulatory Approvalregulatorymid-term

Teva's Gabapentin ANDA205807 Receives Approval Status from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Teva25 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 6:33:39 AM

Assessment confidence: 71% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Teva's approval status for Gabapentin enhances its position in the competitive generic market, potentially affecting pricing strategies and market share dynamics. Pharma strategy teams must evaluate the implications of this approval on their portfolios and competitive positioning. Regulatory context from FDA (FDA AP — GABAPENTIN (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio and strategy teams should assess the implications of this approval on market dynamics and consider strategies to maintain competitive advantage. The strongest clinical anchor is The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Anticonvulsant, 8 regulatory and 3 competitive items passed relevance filtering for Teva.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for TRUTAKNA (BLA761486) by Vera Therapeutics. This approval status may enhance Teva's competitive position in the generic market for Gabapentin, potentially impacting pricing and market share against other generic manufacturers.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — GABAPENTIN (SUPPL) (FDA). Entity match (teva); Regulatory pathway relevance (nda). The approval status indicates progress towards market entry, but final approval and launch timelines remain critical for assessing regulatory compliance and market readiness.

Key Risks

Elevated medium regulatory exposure for Teva could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development) could weigh on Teva through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Teva's entry with an approved generic may lead to price competition, impacting revenue for existing players in the Gabapentin market. Companies must prepare for shifts in market share as generic options expand.
Portfolio and strategy teams should assess the implications of this approval on market dynamics and consider strategies to maintain competitive advantage.

What Would Change This Assessment

This becomes more urgent if Monitor the final approval and market entry timeline for ANDA205807, as well as competitor responses in the Gabapentin market.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (ORIG)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View source

The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Different Myofascial Release Techniques on Function in Chronic Non-Specific Neck Pain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Quality of Life in Patients Who Have Undergone Stem Cell Transplant
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical Restraints in Intensive Care Unit Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for TRUTAKNA (BLA761486) by Vera Therapeutics
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Supplemental Application for RINVOQ LQ by AbbVie
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Teva
Gabapentin
competitors in neurology

Commercial impact

medium

Teva's entry with an approved generic may lead to price competition, impacting revenue for existing players in the Gabapentin market. Companies must prepare for shifts in market share as generic options expand.

Regulatory impact

medium

The approval status indicates progress towards market entry, but final approval and launch timelines remain critical for assessing regulatory compliance and market readiness.

What to watch

Monitor the final approval and market entry timeline for ANDA205807, as well as competitor responses in the Gabapentin market.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.